Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
For more than 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.
Eli Lilly and Company is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We do this by putting the 45 million people that depend on our medicines at the centre of everything we do.
Lilly was founded in 1876, and is headquartered in Indianapolis, Indiana, USA. Lilly has more than 36,000 employees worldwide, including over 9,000 in Europe, where it first established itself in 1934.
Lilly´s purpose is the following: Lilly unites caring with discovery to create medicines that make life better for people around the world.
Eli Lilly and Company has provided sponsorship funding to support the CECON conference and have had no input into the organisation or content of the event.
Bausch Health Companies Inc. is an international pharmaceutical company with a range of branded and generic drugs and over-the-counter products, primarily in the fields of cardiology, gastroenterology, neurology, dermatology, and primary care. It manufactures and sells its products in more than 90 countries, including the USA, Canada, Europe, the Middle East, Africa, Asia, and Latin America.
This Congress is supported by the Capital City of Prague.